<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="utf8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Risteys – L12_PSORI_VULG – detailed case counts by code</title>
		<style type="text/css">
body {
	font-family: sans-serif;
}
.bar-plot-full {
	width: 8rem;
	border-radius: 0.1rem;
	background-color: #f2f2f2;
}
.bar-plot-full div {
	background-color: #c7c7c7;
	height: 1rem;
	border-radius: 0.1rem;
}
		</style>
	</head>
	<body>

		<table>
			<tr>
				<th>Source</th>
				<th>Code</th>
				<th>Name</th>
				<th>Case count</th>
				<th>Share of cases (%)</th>
			</tr>

			
				<tr>
					<td><abbr title="Outpatient Hilmo">OUTPAT</abbr></td>
					<td>OUTPAT_ICD10(L400)</td>
					<td>Psoriasis vulgaris</td>
					<td>4960</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 98.84416102032682%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Avohilmo: Primary healthcare outpatient">PRIM_OUT</abbr></td>
					<td>PRIM_OUT_NOT_USED_ICD10(L400)</td>
					<td>Psoriasis vulgaris. Not used in endpoint definition. POSSIBLY INACCURATE IN COMPLEX ENDPOINTS!</td>
					<td>1474</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 29.37425269031487%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD10(L400)</td>
					<td>Psoriasis vulgaris</td>
					<td>889</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 17.716221602231965%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD9(6961A)</td>
					<td>Psoriasis and similar disorders, Other psoriasis</td>
					<td>301</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 5.998405739338382%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(319)_ICD10(L400)</td>
					<td>Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis vulgaris</td>
					<td>250</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 4.982064567556796%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD10(L400)</td>
					<td>General erythroderma, Psoriasis vulgaris</td>
					<td>148</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 2.949382223993623%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(377)_ICD10(L400)</td>
					<td>Apremilast and dimethyl fumarate (psoriasis), Psoriasis vulgaris</td>
					<td>21</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.4184934236747709%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(L400)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Psoriasis vulgaris</td>
					<td>8</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.15942606616181745%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(L400)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Psoriasis vulgaris</td>
					<td>7</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.13949780789159028%"></div>
						</div>
						
					</td>
				</tr>
			

		</table>

	</body>
</html>
